Welcome to our dedicated page for Neuroone Med Technologies news (Ticker: NMTC), a resource for investors and traders seeking the latest updates and insights on Neuroone Med Technologies stock.
NeuroOne Medical Technologies Corp (NMTC) develops cutting-edge thin film electrode solutions for neurological diagnostics and treatment. This page provides centralized access to official company news, including product advancements, regulatory milestones, and strategic developments in the neuromodulation sector.
Investors and healthcare professionals will find timely updates on NMTC's innovations in continuous EEG monitoring, brain stimulation technologies, and minimally invasive therapeutic devices. The curated news collection offers insights into how the company addresses complex neurological disorders like epilepsy and Parkinson's disease.
Key updates include FDA clearances, research partnerships with medical institutions, and advancements in electrode technology for precise neurodiagnostics. All content is sourced from verified releases to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page to stay informed about NMTC's contributions to medical technology and its evolving role in improving neurological care. Check regularly for objective updates on developments impacting the neuromodulation industry and patient treatment paradigms.
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced its third quarter financial results for fiscal 2021, achieving product revenue of $40,000 and collaboration revenue of $17,000, a notable increase from zero revenue in the same quarter last year. Operating expenses totaled $3.0 million, with a net loss of $3.0 million, improved from a net loss of $7.1 million in the prior year. The company completed its first human use of the Evo Cortical electrode at Mayo Clinic and closed a $12.5 million private placement. NeuroOne is on track for further product launches and has uplisted to Nasdaq.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) will host a conference call on August 13, 2021, at 9:00 AM ET to discuss its financial results for the third quarter ended June 30, 2021. The company focuses on innovative surgical solutions for neurological disorders. Notably, NeuroOne successfully achieved its first performance milestone in a partnership with Zimmer Biomet, securing exclusive global distribution rights for its Evo™ patented electrode technology. The company has received FDA clearance for this technology in November 2019.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced its participation in the Alliance Global Partners Virtual MedTech Summer Conference on July 29, 2021. The event will feature one-on-one virtual meetings between investors and management. NeuroOne focuses on developing advanced EEG recording and ablation solutions for neurological disorders like epilepsy and Parkinson's disease. The company recently achieved a key milestone in its distribution agreement with Zimmer Biomet, further enhancing its market position.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) will present at the Access to Giving Virtual Conference on July 15, 2021, at 2 p.m. ET. The conference aims to connect companies with investors for fundraising opportunities. NeuroOne focuses on innovative solutions for neurological disorders, including epilepsy and Parkinson's disease, leveraging patented electrode technology. The company previously achieved a performance milestone with Zimmer Biomet and received FDA clearance for its Evo cortical technology in November 2019. For more details, visit n1mtc.com.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) has formed a six-member advisory board of distinguished neurosurgeons to aid in the development of its radio frequency ablation electrode. This technology aims to record and ablate brain tissue associated with seizure activity, enhancing surgical procedures for neurological disorders. CEO Dave Rosa emphasized the board's vital role in expediting technology that could improve patient outcomes and reduce costs. NeuroOne's Evo technology gained FDA clearance in November 2019, and the partnership with Zimmer Biomet offers exclusive distribution rights and potential milestone payments.
NeuroOne Medical Technologies Corporation (OTCQB: NMTC) announced its uplisting to The Nasdaq Capital Market, set to commence trading on May 26, 2021. This move aims to enhance the company's visibility among investors and institutional firms. CEO Dave Rosa highlighted the team's efforts over the past four years to achieve this milestone. The company specializes in minimally invasive solutions for neurological disorders, and it has secured exclusive distribution rights for its patented Evo electrode technology through a partnership with Zimmer Biomet, which may lead to significant growth opportunities.
NeuroOne Medical Technologies Corporation (OTCQB: NMTC) announced its participation in the Oppenheimer Medtech, Tools and Diagnostics Summit on May 26, 2021. The summit includes an on-demand presentation for registered participants and one-on-one meetings. NeuroOne focuses on minimally invasive solutions for neurological disorders, including epilepsy and Parkinson's disease. The company has received FDA clearance for its Evo cortical technology, developed in partnership with Mayo Clinic and WARF, and is committed to enhancing surgical care options.
NeuroOne Medical Technologies Corporation (OTCQB: NMTC) announced the appointment of Hijaz Haris as Vice President of Marketing, effective April 27, 2021. Previously a Senior Global Marketing Director at Medtronic, Haris brings over two decades of experience in neurology. CEO Dave Rosa highlighted that this appointment addresses a critical gap in leadership and aims to maximize the company's product portfolio. NeuroOne focuses on minimally invasive solutions for neurological disorders and has received FDA clearance for its Evo cortical technology.
NeuroOne Medical Technologies Corporation (OTCQB: NMTC) announced a reverse stock split of 1-for-3, effective March 31, 2021, at 4:01 PM ET. This move is part of their strategy to uplist to a major exchange. CEO Dave Rosa highlighted the importance of this step, alongside new institutional investments for product development. Following the split, the number of shares will decrease, impacting stock options and warrants proportionately. NeuroOne continues trading under the symbol NMTC with a new CUSIP number of 64130M 209. The company focuses on advanced solutions for neurological disorders.
NeuroOne Medical Technologies Corporation (OTCQB: NMTC) announced that CEO Dave Rosa will appear on the Big Biz Show on April 5, 2021, at 1:15 CST. The discussion will center on the impact of electrical stimulation on treatment modalities and NeuroOne's future role. The company focuses on developing minimally invasive solutions for neurological disorders, including epilepsy and Parkinson's disease. NeuroOne recently completed a milestone with Zimmer Biomet for exclusive distribution rights to its Evo cortical technology, which received FDA clearance in November 2019.
FAQ
What is the current stock price of Neuroone Med Technologies (NMTC)?
What is the market cap of Neuroone Med Technologies (NMTC)?
